Overview
Microbiota Restoration in Recurrent C. difficile and COVID-19
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this activity, Dr. Paul Feuerstadt and Dr. Sahil Khanna discuss how the global COVID-19 pandemic presents increasing safety measures for patients with recurrent Clostridioides difficile Infection (rCDI) that are candidates for fecal microbiota transplantation (FMT). In this video-based format, our faculty share why clinicians need to be aware of screening and safety protocols, and how to manage rCDI patients during this unprecedented time.
This activity is intended for gastroenterologists, infectious disease specialists, and other clinicians who care for patients at risk of serious infection.
While the incidence of multiply recurrent C. difficile continues to rise, FMT has emerged as a means to break the cycle. Amid the current COVID-19 pandemic, clinicians should be aware of the additional safety concerns that have arisen. Expert faculty will discuss approaches to FMT including sourcing and screening of donor stool, which requires heightened safety measures during the COVID-19 pandemic. This activity is the first in a series of two educational activities that address the latest data on treating patients who experience rCDI.
Upon completion of this activity, participants will be able to:
• Discuss the burden of recurrent C. difficile
• Review the efficacy and safety of current approaches to using fecal microbiota for transplantation
• Outline the implications of the COVID-19 pandemic on the treatment of recurrent C. difficile
• Discuss the burden of recurrent C. difficile
• Review the efficacy and safety of current approaches to using fecal microbiota for transplantation
• Outline the implications of the COVID-19 pandemic on the treatment of recurrent C. difficile
This activity is supported by an educational grant from Ferring Pharmaceuticals, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Paul Feuerstadt MD, FACG, AGAF
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Gastroenterology Center of Connecticut
Sahil Khanna, MBBS, MS
Associate Professor of Medicine
Gastroenterology and Hepatology
Mayo Clinic
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:
Paul Feuerstadt, MD, FACG, AGAF
Consulting Agreements: Merck and Company, Ferring Pharmaceuticals, Inc., Roche Diagnostics
Speakers' Bureau: Merck and Company
Sahil Khanna, MBBS, MS
Sources of Funding for Research: Ferring Pharmaceuticals, Inc., Rebiotix, Inc
Consulting Agreements: Facile Therapeutics, Inc., Premier Inc., Probiotech LLC, Shire PLC
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches to treating C. difficile infection and reducing recurrent episodes
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
